Hello and welcome to the AIM ImmunoTech fourth-quarter and full-year 2024 update conference call and webcast. (Operator Instructions) Note that this webcast is being recorded at the company's request, ...

A second phase 1 trial plans to evaluate CER-1236, a novel chimeric antigen receptor therapy, for solid tumors.

Q4 2024 Earnings Call Transcript March 31, 2025 Brainstorm Cell Therapeutics Inc. reports earnings inline with expectations.

Every child with autism or ADHD is unique, so a one-size-fits-all approach doesn’t work. Experts stress the importance of ...

Q4 2024 Earnings Call Transcript March 31, 2025 Celcuity Inc. misses on earnings expectations. Reported EPS is $-0.85 EPS, ...

Good afternoon and welcome to the BioCardia year-end 2024 financial results and business update conference call. (Operator Instructions) A webcast replay of the call will be available approximately ...

Health plans often limit physical therapy to 20 or 30 sessions, even for people who may need months of treatment, multiple ...

English and math. In addition to the basic science of the human body, programs focus on understanding the ever-changing ...

Pharming Group excels with RUCONEST and JOENJA, showing strong revenue growth and positive cash flow. Check out my recommendation for PHAR stock.

In recent years, significant progress has been made in understanding tissue regeneration, tumor dynamics and the role of inflammation in these processes.

New research shows an AI-powered chatbot trained to deliver cognitive behavioral therapy significantly reduced anxiety, ...

Cancer Center have created a tool that uses machine learning to assess a non-Hodgkin lymphoma (NHL) patient's likely response ...